跳至主要内容
临床试验/NCT06649253
NCT06649253
招募中
不适用

REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation

Rennes University Hospital3 个研究点 分布在 1 个国家目标入组 50 人2025年3月22日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Leukemia, Lymphoblastic, Acute, Pediatric
发起方
Rennes University Hospital
入组人数
50
试验地点
3
主要终点
Non coding RNA network in CD9 regulation
状态
招募中
最后更新
4个月前

概览

简要总结

B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.

详细描述

B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing despite major therapeutic advances. A research team of the Development and Genetic Institute in Rennes has identified that the expression of CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells, enabling them to persist in niches such as the testis. CD9-associated relapses often arise from these niches. Understanding the regulation of CD9 expression is therefore essential. The hypothesis on which this project is based is that CD9 expression could be orchestrated by ncRNAs. Due to the complexity of deciphering circRNA-miRNA-mRNA networks, an exploration of patient blasts is envisaged in order to delineate a specific non-coding RNA network regulating CD9 expression from bone marrow and blood samples of paediatric-aged patients with B-ALL. If this hypothesis is confirmed, the ncRNAs identified could constitute new specific diagnostic and prognostic markers, or even therapeutic targets. To confirm this hypothesis, bone and blood sampling of newly diagnosed patients will be collected at the diagnosis, after first phase of treatment and at the relapse, if it occurs.

注册库
clinicaltrials.gov
开始日期
2025年3月22日
结束日期
2035年4月1日
最后更新
4个月前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

发起方
Rennes University Hospital
责任方
Sponsor

入排标准

入选标准

  • Under 18 years
  • With established diagnosis of B-ALL
  • Initial diagnosis made in the investigating centre
  • Having received oral and written information about the protocol, or oral only if the patient is unable to read.
  • Having signed a consent form if the patient is capable of giving informed written consent.
  • Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
  • Beneficiary of a social security scheme

排除标准

  • Isolated extramedullary involvement at inclusion
  • Patient of childbearing age without effective contraception.
  • Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.

结局指标

主要结局

Non coding RNA network in CD9 regulation

时间窗: 5 years

description of the network of lncRNAs (circRNAs/miRNAs) involved in the regulation of CD9 present on the surface of blasts at the time of diagnosis of B-ALL (nature of the lncRNAs, level of expression, etc.)

次要结局

  • Non coding RNA network in CD9 regulation as a prognosis factor of disease follow-up(5 years)
  • Non coding RNA network in CD9 regulation as a predictive factor of relapse(5 years)

研究点 (3)

Loading locations...

相似试验